Brief: Kancera Focuses On Fractalkine Blocking Candidate Drugs KAND567 And KAND145

Novakand Pharma AB

12/11/2024 06:09

Nov 12 (Reuters) - Kancera AB  KANC.ST :
    * TO FOCUS ITS BUSINESS ON DEVELOPING COMPANY'S FRACTALKINE
BLOCKING CANDIDATE DRUGS KAND567 AND KAND145
    * WILL SEEK TO ESTABLISH NEW LONG-TERM AND LIFE SCIENCE
FOCUSED
OWNERS, THAT SUPPORT STRATEGY

Source text:  ID:nMFN521kgD 
Further company coverage:  KANC.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))